Le Lézard

Communiqués de presse par sujet : Essais cliniques / Découvertes médicales

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

14 août 2018

09:00
Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing a first-in-class platform of novel therapeutic compounds for the treatment of diseases associated with mitochondrial dysfunction, announced today that it is...

08:00
PHILADELPHIA, Aug. 14, 2018 /PRNewswire/ -- Aevi Genomic Medicine, Inc. (the Company) today announced that it has completed enrollment in Part A (n=64) of its Phase 2 ASCEND clinical trial, which is assessing a mGluR mutation positive genetic subset...

08:00
Biopharmaceutical company Emalex Biosciences (Emalex), the newest member of the Paragon Biosciences (Paragon) portfolio of companies, today announced it acquired Psyadon Pharmaceuticals and the exclusive rights to develop, register and market...

07:18
Realm Therapeutics plc , a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today reports preliminary top-line data from its Phase 2 trial of PR022 in Atopic Dermatitis, as well as...

07:05
In a world that seems increasingly obsessed with image, National Geographic has today unveiled an exclusive and powerful new story, over two years in the making, that asks the question: 'Are we our faces?' To follow the...


13 août 2018

15:27
- Le symbole de distinction Certifié FCSD (Fondation canadienne pour la promotion de la santé digestive) signifie qu'une évaluation indépendante examinée par les pairs confirme l'innocuité et l'efficacité des capsules d'IBgard® pour le soulagement...

15:27
- CDHF Certified Symbol of Distinction designation indicates independent, peer-reviewed assessment which confirms safety and efficacy of IBgard® for Irritable Bowel Syndrome (IBS) symptoms - With more than 120,000 Canadians developing IBS each year,...

12:17
Santé Canada met les Canadiens en garde contre le risque possible de récidive de cancer chez les patients ayant le cancer du sang et des ganglions qui ont reçu une greffe de cellules souches et qui prennent de l'azithromycine (Zithromax) à long...

12:15
Health Canada is warning Canadians of the potential risk of cancer relapse in patients with cancer of the blood and lymph nodes who have undergone stem cell transplant and are taking long-term azithromycin (Zithromax). The drug was being tested in...

08:30
VolitionRx Limited  ("Volition") today announced preliminary data from a prospective, multi-centered Proof of Concept Study of 84 men into the utility of Volition's Nu.Qtm assays to diagnose men with high-grade prostate cancer. Volition panel...

08:30
Neurotrope, Inc. , a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today provided a business update outlining recent clinical development progress and other...

08:00
Escalier Biosciences, BV, a privately held biopharmaceutical company and a leader in the field of immunology, today announced that the first patient has been dosed in a Phase 1/2a study evaluating ESR-114 topical gel in patients with mild-to-moderate...

08:00
Eiger BioPharmaceuticals, Inc. , focused on the development and commercialization of targeted therapies for rare diseases, announced completion of enrollment of the Phase 2 PREVENT study.  PREVENT is a multi-center, placebo-controlled study...

08:00
Sutro Biopharma, Inc., and The Leukemia & Lymphoma Society® , or LLS, are partnering to develop STRO-001, Sutro's CD74-targeting antibody-drug conjugate, to treat relapsed and/or refractory multiple myeloma and non-Hodgkin's lymphoma. CD74 is a...

04:00
Izana Bioscience, a biopharmaceutical company focused on translational medicine, today announced the initiation of a phase II proof-of-concept clinical study of namilumab in ankylosing spondylitis, a debilitating arthritic disease of the spine that...

03:09
Cantargia AB today announced the status of the ongoing phase I/IIa clinical trial CANFOUR investigating the lead compound CAN04 (nidanilimab) and further information on the phase IIa part of the trial. So far, 15 patients have received therapy...


10 août 2018

13:44
The U.S. Food and Drug Administration today approved Onpattro (patisiran) infusion for the treatment of peripheral nerve disease (polyneuropathy) caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adult patients. This is the first...

13:20
Kyowa Hakko Kirin Co., Ltd., (Kyowa Kirin) announced today that results of the global Phase 3 MAVORIC study (Mogamulizumab anti-CCR4 Antibody Versus ComparatOR In CTCL) investigating the use of mogamulizumab in patients with cutaneous T-cell lymphoma...

07:15
Prometic Sciences de la Vie Inc. (« Prometic ») a...

07:15
Prometic Life Sciences Inc.  ("Prometic") today announced the publication of a paper further elucidating the mechanism of...

06:10
Researchers at Okayama University report in The Journal of Vascular Access a supporting device for accurately placing hemodialysis catheters on kidney patients. The device was successfully used on a group of 10 patients and is expected to become an...

04:18
Swedish Orphan Biovitrum AB (publ) (Sobitm) announces that the first patient has been dosed in the phase 1/2 study SOBI003-001. The study is an open-label, non-controlled, multiple-dose study with the objective of assessing the safety, tolerability...


9 août 2018

21:24
JHL Biotech has announced it received a positive Scientific Advice from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) related to the EU approval pathway for its proposed trastuzumab biosimilar,...

21:24
JHL Biotech has announced it received a positive Scientific Advice from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) related to the EU approval pathway for its proposed bevacizumab biosimilar,...

14:54
InDex Pharmaceuticals Holding AB (publ) today announced an updated timeline for patient recruitment in the ongoing phase IIb study CONDUCT with the drug candidate cobitolimod. Top line results from the study are now expected in the first half of 2019...

09:05
Prolacta Bioscience®, the pioneer in human milk-based neonatal nutritional products for premature infants, announced today that enrollment has passed the halfway milestone in a randomized controlled study evaluating how growth and clinical outcomes...

09:03
A new study released by the European Vulvovaginal Epidemiological Survey (EVES) concludes that vulvovaginal atrophy (VVA), or thin dry vaginal and vulvar tissues, is highly prevalent among postmenopausal women and can be associated with severe...

08:30
VolitionRx Limited  ("Volition") today announced that the 3-year sample collection has been completed in the prospective study undertaken in collaboration with the University of Oxford, England to assess Volition's proprietary Nu.Qtm platform...

08:10
The global drug discovery outsourcing market size is expected to reach USD 4.44 billion by 2025 at an 8.14% CAGR, according to a new report by Grand View Research, Inc. Urging need to identify potential drug candidates for various chronic diseases is...

08:01
BioSpecifics Technologies Corp. , a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced...

08:00
Relmada Therapeutics, Inc. , a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that the State Intellectual Property Office of China has issued a Decision to Grant for...

08:00
Agenus Inc. , an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, provided a corporate update and reported financial results for the second quarter of 2018....

05:05
BeiGene, Ltd. , a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, announced today that the first patient was dosed in a Phase...

04:16
In July, 2018, I-Mab Biopharma (I-Mab) announced that it received clinical trial approval from China National Drug Administration (CNDA) for TJ103 (TG103) injection: an innovative, humanized, long-acting recombinant glucagon-like peptide-1 (hGLP-1)...


8 août 2018

17:22
Gala Therapeutics (Gala), a clinical-stage developer of medical devices to treat pulmonary disease, today announced that data from a Late-Breaking Abstract from a first-in-human study of the Rheoxtm system will be presented at the European...

16:01
Sangamo Therapeutics, Inc. today announced positive preliminary data from the Phase 1/2 clinical trial evaluating SB-525, a cDNA gene therapy candidate for Hemophilia A (the "Alta study"). SB-525 is being developed as part of a global collaboration...

15:32
The Harrington Discovery Institute at University Hospitals in Cleveland, Ohio?part of The Harrington Project for Discovery & Development?has announced three new scholars in collaboration with its partners Foundation Fighting Blindness (FFB) and...

12:51
International Biophysics Corporation, a 26-year-old global medical device manufacturer based in Austin, Texas, announced today the publication of a clinical study on the mode of action of High Frequency Chest Wall Oscillation (HFCWO) vests.  The...

09:14
Milestone Pharmaceuticals, a clinical-stage cardiovascular company, today announced that the first patient has been randomized in its Phase 3 clinical study of etripamil. Etripamil is a new investigational, rapid-onset, short-acting calcium channel...

08:30
SQZ Biotechnologies (SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, announced the completion of an oversubscribed $72 million Series C financing.  New investors include Everblue, Illumina Ventures, Invus,...

08:30
BiondVax Pharmaceuticals Ltd. reported today the first participant's initial visit in a pivotal clinical efficacy Phase 3 trial of the M-001 universal flu vaccine candidate. The primary endpoints of the trial are to demonstrate protection from...

07:30
REGENXBIO Inc. , a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced financial results for the quarter ended June...

07:30
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) and a Type II Variation to the European Medicines Agency...

07:00
Canopy Growth Corporation (« Canopy Growth » ou « la société ») et ses filiales en propriété exclusive, Canopy Health Innovations Inc. (« Canopy Health » ou « CHI ») sont heureuses d'annoncer qu'elles ont reçu l'approbation de la Direction des...

07:00
BELLUS Santé inc. (« BELLUS Santé » ou la « société »), une société biopharmaceutique au stade clinique qui développe de nouveaux médicaments ciblant des maladies pour lesquelles il existe d'importants besoins médicaux non comblés, a annoncé...

07:00
BELLUS Health Inc. ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for conditions with high unmet medical need, today reported its financial and operating results for the second quarter...

07:00
Canopy Growth Corporation ("Canopy Growth" or the "Company") and its wholly owned subsidiary, Canopy Health Innovations Inc. ("Canopy Health" or "CHI") is pleased to announce that approval has been received from the Veterinary Drug Directorate of...

06:00
Apexigen, Inc., a clinical-stage biopharmaceutical company, today announced the successful completion of its Series B and Series C financings in which it raised a total of $73 million. The $15 million Series B financing was led by Decheng Capital...

06:00
United Therapeutics Corporation today announced that preliminary analysis indicates that the FREEDOM-EV clinical study of Orenitram® (treprostinil) extended-release tablets in patients suffering from pulmonary arterial hypertension (PAH) has met its...

04:00
Actisound technology uses Intense Therapeutic Ultrasound to treat musculoskeletal injuries  CE Approval comes as Guided Therapy Systems launches across Europe  Guided Therapy Systems, a world leader in ultrasonic therapy and imaging technologies,...

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17